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With the demographic shift in age in advanced countries inexorably set to progress in the 21st century, dementia will become one
of the most important health problems worldwide. Vascular cognitive impairment is the second most common type of dementia
after Alzheimer’s disease and is frequently responsible for the cognitive decline of the elderly. It is characterized by cerebrovascular
white matter changes; thus, in order to investigate the underlying mechanisms involved in white matter changes, a mouse model
of chronic cerebral hypoperfusion has been developed, which involves the narrowing of the bilateral common carotid arteries
with newly designed microcoils. The purpose of this paper is to provide a comprehensive summary of the achievements made
with the model that shows good reproducibility of the white matter changes characterized by blood-brain barrier disruption,
glial activation, oxidative stress, and oligodendrocyte loss following chronic cerebral hypoperfusion. Detailed characterization of
this model may help to decipher the substrates associated with impaired memory and move toward a more integrated therapy of
vascular cognitive impairment.
1.Introduction
Subcortical ischemic vascular dementia (SIVD) is character-
ized by white matter (WM) changes and lacunar infarctions,
which occur as a result of a reduction in cerebral blood ﬂow
(CBF) over an extended period of time, causing small vessel
changes [1–3]. Cerebrovascular WM lesions, neurodegener-
ativemanifestationscharacterizedbyhyperintensesignalson
magnetic resonance images, are frequently associated with
aging and are responsible for the cognitive decline in the
elderly population [1–7]. Chronic cerebral hypoperfusion
is likely to cause such WM lesions as CBF is decreased
in these patients [2, 8]; indeed, similar WM lesions can
be induced in rats, gerbils, and mice after chronic cerebral
hypoperfusion, with experimental conditions mimicking
chronic cerebral ischemia in humans [9–11]. These model
animals can be generated by bilateral common carotid
artery (CCA) occlusion in rats (2-vessel occlusion (2VO))
[9, 12, 13]o ri nm i c e[ 14], bilateral CCA stenosis in mice
(BCAS) [10] or in gerbils [11], and unilateral CCA occlusion
in mice [15]. Nonhuman primates appear to represent the
best model for the study of WM lesions, because they have
well-developed WM and vascular architectures which closely
resemble those in human brains [16]. Nevertheless, most
experiments studying chronic cerebral hypoperfusion have
been performed in rodents because of the ease of handling
and higher acceptability from an ethical viewpoint.
The rat model of chronic cerebral hypoperfusion is
accompanied by cognitive impairment and cholinergic
deﬁcits [9, 13, 17] and is most widely used [12, 18]. These
animals develop WM rarefaction [9, 19], which appears very
similar to that found in human cerebrovascular WM lesions.
However, this model has some drawbacks. For example, the
visual pathway is injured by the occlusion of the ophthalmic
arteries and thus may compromise behavioral assessment.
Furthermore, genetic studies may be hampered because2 Journal of Aging Research
of limited accessibility to molecular technologies when
using knockout or transgenic animals. To circumvent such
limitations, we have established a mouse model of chronic
cerebralhypoperfusion,whichissubjectedtovariousdegrees
of CBF reduction by the narrowing of the bilateral CCAs
with newly designed microcoils. The model demonstrates
good reproducibility in terms of WM lesion appearance and
glial activation. The cerebral WM is selectively damaged,
whilegraymatter(includinghippocampal)integrityremains
intact, if the degree of stenosis is appropriately controlled by
internal diameter regulation of the microcoils [10].
The aims of the current paper are to provide a com-
prehensive survey of the experimental evidence that has
accumulatedsince establishment of this mouse BCAS model,
in order to extrapolate the results into human neurological
conditions, and to consider the particular strengths and
pitfalls of the method.
2. The Procedures for BCAS
Ten-week-old male C57BL/6J mice (24–29g) are conven-
tionally used to induce chronic cerebral hypoperfusion by
BCAS [10, 20, 21]. This model should be applied exclusively
to C57BL/6J strain, because the CBF in the other strains
may have a greater variability after BCAS. In this paper,
unless stated otherwise, the “BCAS mouse” indicates a male
C57BL/6J mouse that is subjected to BCAS for 30 days from
10 weeks of age using microcoils of 0.18mm in diameter.
Mice are anesthetized with 2% halothane or 25–
50mg/Kg sodium pentobarbital and, through a midline
cervicalincision,bothCCAsareexposedandfreedfromtheir
sheaths.Two4–0silksuturesareplacedaroundthedistaland
proximal parts of the right CCA. The artery is then gently
lifted by the sutures and placed between the loops of the
microcoil just proximal to the carotid bifurcation (Figures
1(a) and 1(b)). The microcoil is twined by rotating it around
the CCA, and another microcoil of the same size is twined
aroundtheleftCCAafter30minutes(Figures1(b)and1(c)).
Four types of microcoils made from piano wire with varying
inner diameters from 0.16mm to 0.22mm (Figure 1(c))
have been designed in collaboration with Sawane Spring
Co., Ltd. (Hamamatsu, Japan). Microcoils with the same
diameter are conventionally placed on the bilateral CCA,
though a modiﬁed model has also been devised where the
0.16mmmicrocoilisplacedontheleftCCAandthe0.18mm
microcoil on the right CCA [22]. The rectal temperature
should be maintained between 36.5◦C and 37.5◦C, and the
cessation of CBF for >1 minute should be avoided. All
procedures for BCAS are usually accomplished within 15
m i n u t e se x c e p ta ni n t e r v a lf o r3 0m i n u t e s .
2.1.Blood Pressure. The blood pressure of the surviving mice
does not change signiﬁcantly at any postoperative intervals
until 30 days, compared with the sham-operated controls
[10].
2.2. Mortality Rates. The mortality rates are reported to
range from 10% to 20%: 13% in mice with microcoils of
0.22mm in diameter, 17% in those of 0.20mm, and 15–19%
in those of 0.18mm [10, 23]. In contrast, 75% (15/20) of
mice with microcoils of 0.16mm placed died within 14 days
after the surgery, most of whom were found to have cerebral
infarctions [10]. In another study of a modiﬁed model with
the 0.16mm microcoil on the left CCA and the 0.18mm
microcoil on the right CCA, the mortality rate is reported
to be 18.8% [22].
2.3. Body Weight. Body weight has been shown to decrease
after the surgery, but recover to baseline by day 7, in
mice with 0.22, 0.20, and 0.18mm diameter microcoils.
Althoughthemicewiththe0.22,0.20,and0.18mmdiameter
microcoils placement tended to have a lower body weight
than those with sham operation, no signiﬁcant diﬀerence
is noted at any postoperative interval. In contrast, the mice
with the 0.16mm diameter microcoil placement showed
signiﬁcantly lower body weight at all postoperative intervals,
compared with the sham-operated mice [10].
2.4. Neurological Deﬁcits. After placement of the 0.22, 0.20,
and 0.18mm diameter microcoils, the animals regained
consciousness within a few hours and occasionally showed
transientptosisbutnoapparentmotorweakness.Incontrast,
some of the mice with 0.16mm diameter microcoils placed
(∼35%) did not regain consciousness, showing rolling or
circling movements lasting 2 to 6 hours after awakening, and
severe akinesia with a squatting posture [10].
2.5.Anesthetics. Althoughanestheticssuchassodiumpento-
barbital and halothane are known to provide varying degrees
ofneuroprotectionagainstischemicinjury[24],theselection
of anesthesia did not appreciably aﬀect the mortality rates,
temporal proﬁle of CBF, and ischemic WM changes after
BCAS.
3. TheSpatialandTemporalProﬁlesofCerebral
Blood Flow andMetabolism after BCAS
Although 2VO rats develop speciﬁc WM changes without
any apparent gray matter changes [9, 12], 2VO in mice will
inevitably lead to a severe drop in CBF due to underde-
veloped posterior communicating arteries [25]. Therefore,
in mice, carotid stenosis, but not occlusion, is required to
achieve cerebral hypoperfusion and resultant WM changes.
CBF and cerebral metabolism change dynamically following
the BCAS operation, with CBF dropping immediately after
carotid stenosis and recovering over a period of months
via compensatory and adaptive mechanism (i.e., collateral
anastomosis).
Figure 2 shows mean CBF values evaluated with laser
Doppler ﬂowmetry in surviving mice of 2.5 months of age
after application of four types of piano wire with varying
inner diameters, varying from 0.16mm to 0.22mm, to the
bilateral CCAs [10]. The CBF values decreased signiﬁcantly
from the preoperative baseline after the surgery with the
0.20, 0.18, and 0.16mm diameter microcoils. At 2 hours,
there was a signiﬁcant reduction in CBF values in mice withJournal of Aging Research 3
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Figure 1: The procedure for BCAS and the microcoil. The microcoil is twined by rotating it around the CCA just proximal to the carotid
bifurcation of a C57BL/6J mouse (a). Representative photographs of a FITC-perfused common carotid artery before (left) and after (right)
placement of a microcoil (b). The microcoil is made from piano wire (wire diameter of 0.08mm) with an inner diameter of 0.18mm, pitch
0.50mm, and total length 2.5mm (c).
the 0.20mm microcoils to 77.3±13.4% (mean ± SD), 67.3±
18.5%inthosewith0.18mm,and51.4±11.5%inthosewith
0.16mm. On day 1, the CBF values started to recover but
remained signiﬁcantly lower until 14 days after placement
of the microcoils, compared with the control group. At 30
days, CBF values were still decreased in mice with 0.16mm
microcoils placed. Intergroup diﬀerences in CBF values were
detected between mice with 0.16mm microcoils but there
were no diﬀerences among the mice with 0.22, 0.20, and
0.18mm microcoils placed.
Older 4-month-old mice showed a similar proﬁle of CBF
changesaftertheBCASoperationwiththe0.18mmcoils;the
CBF values temporarily decreased to 62.9 ± 18.5% (mean ±
SE) at 2 hours after BCAS, compared to the sham group but
gradually recovered to 81.7% ± 4.0% at 1 month, 83.2% ±
1.8% at 2 months, and 85.0% ± 8.7% at 3 months [26].
Interestingly, this temporal proﬁle of CBF is similar to that of
the ﬁrst 5-minute 18F-ﬂuorodeoxyglucose (FDG) uptake in
the cerebral cortex, suggesting that the early 18F-FDG uptake
scan can serve as an estimate of CBF. The early 18F-FDG
uptakescaninthestriatumshowedasimilartemporalproﬁle
to that of the cerebral cortex, suggesting that the CBF values
in the cerebral cortex and the striatum change in parallel
after BCAS. By contrast, the CBF in the hippocampus did
not decrease at 2 hours or 2 months after BCAS but ﬁnally
decreased at 6 months. The late 18F-FDG scans show that
the glucose uptake in the hippocampus did not decrease by
2 months after BCAS but decreased by 20% at 6 months
after BCAS. The lack of reductions in hippocampal CBF and
metabolism in the early phase after BCAS is probably due
to the hippocampus being supplied by both anterior and
posterior circulations [27]. However, mild cerebral ischemia
of an insuﬃcient magnitude for 6 months has been shown to
induce subacute pathologies, which may lead to subsequent
changes in the gray matter, including the cerebral cortex and
hippocampus [26].
4. Blood-Brain Barrier Disruptionafter BCAS
A previous study on the rat 2VO system and human
material implicated a dysfunction of the blood-brain barrier
(BBB), perivascular edema, and microglial activation as
the mechanisms underlying the WM lesions [9, 28, 29].
During this process, microglia may play a pivotal role;
both microglia activation and WM lesions have been shown
to occur concurrently, and both are suppressed by the
administration of immunosuppressants, such as cyclosporin
Ao rF K5 0 6[ 30, 31]. Proteases derived from the microglia
may contribute to the reduction in the basement membrane
components and BBB breakdown [32, 33]. The resulting
perivascular edema may further exacerbate the degradation
of the WM myelin through the actions of extravasated serum
factors [28]. The BBB breakdown also leads to leukocyte4 Journal of Aging Research
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Figure 2: Cerebral blood ﬂow after BCAS. This ﬁgure shows
cerebral blood ﬂow evaluated with laser Doppler ﬂowmetry in
mice at 2.5 months of age after the surgery using microcoils with
diameter of 0.16mm, 0.18mm, 0.20mm, and 0.22mm. The data
represent mean values expressed as a percentage of the preoperative
value.
diapedesis [34], and the inﬁltrating leukocytes may cause
inﬂammatory demyelination. Matrix metalloproteinase-2
(MMP-2), through its activity as a type IV collagenase,
is activated and degrades components of the basement
membrane. In addition, MMP-2 has been shown to degrade
myelin basic protein at approximately 100x more potency
than MMP-9 [35]. Thus, the MMP-2 released from glial cells
may be directly involved in the remodeling of WM myelin
[36].
Consistent with the aforementioned notion, BBB disrup-
tion has been shown to be accompanied by an upregulation
of MMP-2, but not MMP-9, suggesting the speciﬁc involve-
ment of MMP-2 in WM lesion manifestation in the 2VO rat
model [37]. In rats treated with a relatively selective MMP-2
inhibitor, AG3340, the WM lesions become signiﬁcantly less
severe after chronic cerebral hypoperfusion, and the density
of activated astroglia and microglia signiﬁcantly reduced,
compared with the vehicle-treated rats [21]. Gene knockout
of MMP-2 also reduced the severity of WM lesions and
the density of activated astroglia and microglia in a mice
BCAS system. In both rodents, disruption of BBB function,
as assessed by IgM staining and the Evans blue extravasation
test, was less severe when MMP-2 activity was attenuated.
The most marked extravasation in Evans blue test, in the
paramedian portion of the corpus callosum facing the lateral
ventricle in the BCAS mouse, is consistent with a previous
report on a rat model of chronic cerebral hypoperfusion
[38] and further indicates a vulnerability of the BBB in this
area. Rosenberg et al. showed that the activated astroglia and
microglia/macrophages present around arterioles express
MMP-2 and MMP-3, but not MMP-9, in the brains of
patients with vascular dementia [39]. The major pathologic
features of WM lesions, such as demyelination and gliosis,
may result from a BBB dysfunction, which may result in
the leakage of proteins and ﬂuid through the compromised
barrier of the penetrating arteries [40].
5. White Matter Injuryafter BCAS
In BCAS mice with 0.18mm microcoils placed, the temporal
proﬁle of the WM lesions was examined (Figure 3)[ 10, 20,
21, 41–43]. WM lesions were not detected in any region of
the brain 3 and 7 days after BCAS. After 14 days, the WM
lesionswereevaluatedasgrade0or1inthemedialpartofthe
corpus callosum, caudoputamen, and the internal capsule;
however, after 30 days, severe rarefaction occurred in these
regions. WM lesions were most densely distributed in the
medial part of the corpus callosum adjacent to the lateral
ventricles; the lesions were moderately distributed in the
paramedian part of the corpus callosum, ﬁber bundles of the
caudoputamen, and the internal capsule; lesion distribution
was, however, less severe in the anterior commissure and the
optic tract. The staining intensity of the myelinated ﬁbers
was reduced and the integrity of the myelin compromised
in the WM regions. The remaining ﬁbers were disorganized
and vacuoles frequently observed in the neuropil. There were
relatively few TUNEL positive cells in the corpus callosum
[20]. In contrast, the WM lesions in the optic tract did
not emerge until 30 days. Atrophy was not found in the
optic nerve, though there was evidence of slight rarefaction.
In each region of the WM, the numerical densities of the
microglia/macrophages immunolabeled for MHC class II
antigen increased signiﬁcantly from 7 to 30 days after BCAS
whereas astroglia immunolabeled for GFAP increased in the
period from 14 to 30 days and the regions with intense glial
activation corresponded to those with a greater loss of WM
myelin. There was a signiﬁcant negative correlation between
the CBF at any time point after BCAS and the grading scores
of WM lesions at 30 days [10]. Thus, lower CBF appears to
be present in the more severe WM injuries. This notion is
further strengthened by the ﬁnding that mice with 0.16mm
microcoil on the left CCA and 0.18mm microcoil on the
right CCA exhibited more severe WM injury in the left
hemisphere [22].
In accordance with the histological ﬁndings, in vivo
MRI showed reductions in fractional anisotropy in the
corpus callosum and internal capsule and a signiﬁcant
decrease in the magnetization transfer ratio in the corpus
callosum, ﬁmbria, internal capsule, and optic tract follow-
ing hypoperfusion [44]. Hypoperfused mice demonstrated
diﬀuse axonal and myelin pathology, which was essentially
absent in control mice. Both fractional anisotropy and
magnetization transfer ratio correlated with markers of
myelin integrity/degradation and not axonal pathology.
Furthermore, in a rat 2VO model, an increase in apparent
diﬀusion coeﬃcients on MRI was reported to be linked withJournal of Aging Research 5
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Figure 3: White matter changes after BCAS. Photomicrographs of Kl¨ uver-Barrera staining in the cerebral cortex (a, b), corpus callosum
(c, d), and caudoputamen (e, f). The left column (a, c, e) indicates the brain from a sham-operated mouse, and the right column (b, d, f)
indicates a brain after BCAS-operated mouse using microcoils with 0.18mm diameter for 30 days. Note that the WM changes are the most
intense in the medial part of the corpus callosum adjacent to the lateral ventricle (arrows). The histogram shows temporal proﬁles of the
WM changes, the severity of which is semiquantitatively graded into four levels (g). Scale bar, 500μm( a ,b ) ,5 0μm (c, d), and 25μm( e ,f) .6 Journal of Aging Research
MMP-2 or -9 activity and edema in WM [45]. These data
therefore suggest that in vivo MRI is a sensitive measure
of vasogenic edema and WM changes in the murine brain
[44, 45].
6. Impairmentof Learningand
Memory after BCAS
In working memory tasks, tested with the 8-arm radial maze,
BCAS mice made signiﬁcantly more errors than the control
mice following one month of hypoperfusion, although they
did show normal spatial reference memory in the 8-arm
radialmazetest[20].Spatialreferencememorytaskisrelated
to cognitive domains likely to rely on the integrity of the
hippocampus, and therefore preserved reference memory is
in agreement with lack of histological damage in the hip-
pocampus [10]. In contrast, working memory impairment
maybeattributabletoeitherthefrontalWMlesionsobserved
and/or hippocampal damage, which is undetectable by
the conventional histological methods. In previous studies,
working memory deﬁcits have been related either to the
hippocampus or frontal subcortical circuits in the rodent
[13, 46] and likely primates [47, 48]. Therefore, disruption
of WM tracts, especially within the prefrontal cortex, may be
another mechanism behind age-related changes in working
memory function [49]. A previous study has also shown that
there is a selective impairment in spatial working memory,
with all other measures of spatial memory remaining intact,
in the BCAS mice with selective WM damage [42].
In contrast, in the longer-term BCAS model, in addition
to WM changes, there were also signiﬁcant hippocampal
changes (atrophy and cell death) documented 8 months
afterBCAS (seeSection 7). Consistent with these histological
changes, a series of behavioral batteries demonstrate deﬁcits
in both working and reference memory. Thus, longer-
term hypoperfusion more accurately replicates the advanced
stages of SIVD and possibly provides evidence linking
chronic hypoperfusion and aging [26].
7. Neuropathologic Changes Induced byBCAS
No infarctions or hemorrhage develops in any gray matter
regions in mice with the 0.22, 0.20, and 0.18mm microcoils
after 1 month of chronic cerebral hypoperfusion [10]. There
are no TUNEL positive neurons in the hippocampus [20].
In contrast, more than half of the BCAS mice with 0.16mm
microcoils placed exhibited microinfarcts in the parietal cor-
tices, neuronal loss in the CA1 subﬁeld of the hippocampus,
and patchy necrotic lesions in the caudoputamen [10].
In contrast, at 8 months after BCAS, pyknotic neurons
have been frequently observed in the cerebral cortex and
the hippocampus. Furthermore, signiﬁcant atrophy has been
noted in the hippocampus but not in the cerebral cortex or
thecorpuscallosum.Thenumberoffragmentedorshrunken
nuclei stained for single-stranded DNA increased in the CA1
and CA3 sectors of the hippocampus but not in the dentate
gyrus.
Given that the shorter-term (conventional) BCAS mice
demonstrate WM damage without any apparent hippocam-
pal damage at 1 month after BCAS, hippocampal degen-
eration in the longer-term BCAS mice may be secondary
to the preceding WM damage. This may then subsequently
contribute to the dementia syndrome, partly overlapping
with Alzheimer’s disease (AD) in their cognitive proﬁles
and histological changes. In probable AD patients, a linear
relation is found between WM lesions and hippocampal
atrophy on MRI, especially for WM lesions in the frontal
and parietooccipital regions [50]. A disconnection of the
hippocampus by cerebrovascular WM lesions in the white
matter tracts subserving the cortical association areas may
lead to shrinkage of the hippocampus due to Wallerian
degeneration as the hippocampus receives most of the input
fromtheneocorticalassociationcortices[51].Theseﬁndings
are intriguing given the widely accepted fact that vascular
dementia and AD both increase in prevalence with age,
frequently occur concomitantly, and overlap considerably
in their symptomatology, pathophysiology, and comorbidity
[52]. WM damage may thus be one of the pathological
substrates that mediates such a linkage between neurodegen-
erative and cerebrovascular disorders.
8. BCAS-Mediated Acceleration of
Neurodegeneration: Linkage between
Hypoperfusion and Neurodegeneration
WM attenuation has also been frequently observed in
neurodegenerative disorders, such as AD and dementia with
Lewy bodies [53]. MR imaging has revealed that such
changes manifest as WM lesions, which increase with older
age [54] ;t h i si sp a r t i c u l a r l ya p p a r e n ti nA Da n dd e m e n t i a
with Lewy bodies, compared to ageing controls, though to a
lesser extent than in vascular dementia. WM lesions in AD
progress relatively slowly if a multicomponent intervention
is given to reduce vascular risk factors [55], suggesting
that ischemic changes underlie the WM lesions in AD.
However, diﬀerent mechanisms have been, at least to a
certain extent, associated with myelin degeneration as it
has been shown that myelin loss evolves in parallel with
shrunken oligodendrocytes in vascular dementia but with
their increased density in AD [56]. Further investigation
is thus warranted to clarify the wider question of whether
vascular brain injury has additive eﬀects on AD pathogenesis
[57–59]. To tackle this question, AD model mice have been
subjected to chronic cerebral hypoperfusion by BCAS.
Biochemical analyses have indicated that BCAS increases
the level of conformationally changed Aβ in soluble
extracellular-enriched brain fractions in a relatively low-(J9)
[60] and high-expressor line (J20) of the APPSw/Ind mouse
[61]. The latter study also demonstrated that BCAS signiﬁ-
cantly reduced the density of cored plaques and neurons of
the hippocampus [61]. Notably, chronic cerebral hypoper-
fusion and APPSw/Ind overexpression interdependently dis-
rupted reference memory [61]. Therefore, soluble, but not
insoluble, Aβ species may play a direct role in neurotoxicity
and resultant behavioral abnormalities in the hypoperfusedJournal of Aging Research 7
APPSw/Ind mice. Since the vascular-type lesions reproduced
in the BCAS model are oligemic (e.g., noninfarctional)
chronic hypoperfusion may accelerate AD neuropathology
in a latent manner over an extended period of time via
enhanced neuronal loss and altered Aβ metabolism. Given
that oligodendrocytes are highly susceptible to Aβ toxicity
[62], the results may further provide evidence linking
chronic hypoperfusion with neurodegeneration.
9. Treatment:FutureDirectionsonIntervention
9.1. MMP Inhibitor. The MMP inhibitor AG3340 has been
shown to possess protective eﬀects against WM lesions after
chronic cerebral hypoperfusion in rats [21]. AG3340 admin-
istration has been shown to decrease IgM-immunoreactive
glial cell density in the vicinity of the microvessels in the
corpus callosum, suggesting it helps restore BBB integrity
[21, 37]. Furthermore, genetic deletion of MMP-2 has been
shown to attenuate the WM lesions after BCAS in mice.
These data suggest the potential value of MMP inhibitors
in preventing SIVD resulting from BBB dysfunction and
chronic cerebral ischemia in humans [39]. An elucidation of
theexactrolesofMMP-2inBBBdisruptionmayalsoprovide
information useful in developing strategies for controlling
WM damage.
9.2. Adenosine A2A Ligand. As an endogenous neuromod-
ulator in the brain, the extracellular levels of adeno-
sine markedly increase under hypoxic/ischemic conditions.
Adenosine exerts its physiological actions through activation
of four G-protein-coupled membrane receptors, the A1,A 2A,
A2B,a n dA 3 receptors [63]. The A2A receptor has drawn
attention for its ability to modify a variety of brain insults;
for instance, mice deﬁcient in the A2A receptor have been
shown to possess substantially smaller infarct volumes and
better neurological behavioral deﬁcit scores after transient
focal ischemia [64]. A2A receptor antagonists have also been
shown to attenuate ischemic brain injury [65], suggesting
a neuroprotective role of A2A in acute ischemic injury.
However, adenosine’s action is likely to be diverse in the
setting of brain injury as brain damage aggravates after
hypoxic ischemia in immature A2A knockout mice [66].
A recent study has further indicated that, following the
BCAS operation, A2A receptor knockout mice display more
extensive demyelination-related damage together with pro-
liferation of astrocytes and microglia in the WM, compared
with wild-type mice [23]. Working memory, evaluated by
means of an 8-arm radial maze test, is also more seriously
impaired in A2A receptor knockout mice relative to wild-
type mice. Such eﬀects have been associated with increased
expression of proinﬂammatory cytokines, including tumor
necrosis factor-α, interleukin-1β, and interleukin-6 in the
WM. Therefore, activation of the A2A receptor by its ligand
may ameliorate the WM damage and cognitive deﬁcits
induced by BCAS through suppression of proinﬂammatory
cytokines. Although the A2A receptor may be a potential
therapeutictargetforthetreatmentofischemicWMdamage,
apotentialpitfallintheirusemaybetheirapparentopposing
eﬀects on diﬀerent cell types such as neurons, inﬂammatory
cells, and glial cells.
9.3. Angiotensin II Type 1 Receptor Blocker. Drugs that
target the rennin-angiotensin system seem to have partic-
ular potential for prevention of dementias, including AD
and vascular dementia. The Perindopril Protection Against
Recurrent Stroke Study (PROGRESS) has suggested a pro-
tective eﬀect of angiotensin-converting enzyme inhibitors on
cognitivefunctioninpatientswithstroke[67].Moreover,the
Study on Cognition and Prognosis in the Elderly (SCOPE)
trial demonstrated a positive eﬀect of the angiotensin II type
1 receptor blocker (ARB), candesartan, in a subgroup of
elderlyhypertensivepatientswithmildcognitiveimpairment
[68]. Notably, a prospective cohort analysis of 819491
participants has suggested that ARBs are associated with
a signiﬁcant reduction in the incidence and progression
of dementia, even compared with angiotensin-converting
enzyme inhibitors [69].
In accordance with the above clinical ﬁndings, telmisar-
tan, an ARB with unique “delta lock” structure that strongly
binds to angiotensin II type 1 receptor [70], and possesses a
high degree of lipophilicity and thus the ability to cross the
blood-brain barrier [71], has been shown to exert protective
eﬀects against WM damage and cognitive impairment in the
BCAS mice [41]; it is thought to achieve this by alleviating
microglial/astroglial activation, endothelial oxidative stress,
and oligodendrocyte loss [41]. Notably, such protective
eﬀects are observed with a nonhypotensive dose, but not
with a hypotensive dose of telmisartan, suggesting that such
protective eﬀects against WM lesions are independent of
blood pressure, and are at least partially mediated by anti-
inﬂammatory and antioxidative eﬀects that are exerted in
part by the pleiotropic eﬀects of telmisartan such as PPAR-
γ activation [41, 71]. Thus, telmisartan may be considered
as a putative treatment for SIVD, though caution should be
exercised when lowering blood pressure if cerebrovascular
autoregulation is damaged. In clinical practice, appropriate
timing and dose of telmisartan should be considered.
9.4. Adrenomedullin. Adrenomedullin (AM) has a variety
of eﬀects on the vasculature that include vasodilation,
regulation of permeability, inhibition of endothelial cell
apoptosis and oxidative stress, regulation of smooth muscle
cell proliferation, and promotion of angiogenesis [72, 73].
AM heterozygosity in mice resulted in increased infarct
volume with signiﬁcant accumulation of inducible nitric
oxide, oxidative DNA damage, and lipid peroxidation after
transient focal ischemia [74] whilst prophylactic adminis-
tration of AM alleviated cerebral edema in the striatum
and cerebral cortex in a rat stroke model [75]. In BCAS
mice, increased levels of circulating AM have been shown to
restore cerebral hemodynamics, promote arteriogenesis, as
well as angiogenesis, alleviate oxidative damage in cerebral
microvessels, and preserve WM integrity; importantly, this
subsequently attenuates working memory deﬁcits in an 8-
arm radial maze test [43]. In addition, AM selectively upreg-
ulates brain levels of cyclic AMP, vascular endothelial growth8 Journal of Aging Research
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Figure 4: A schematic illustration of oligovascular niche. In the “oligovascular niche,” crosstalk between endothelial cells and
oligodendrocytes mediated by an exchange of soluble signals (e.g., trophic factors or chemical messengers) might play an important role
in sustaining oligodendrocyte homeostasis and WM integrity. Since oxidative stress and inﬂammation caused by cerebral hypoperfusion
would be detrimental for this niche, maintenance of white matter integrity or oligovascular protection could be achieved by proangiogenic,
antioxidative, and anti-inﬂammatory interventions. OPC: oligodendrocyte precursor cell.
factor, and basic ﬁbroblast growth factor in the hypop-
erfused, but not the normoperfused, brain. Furthermore,
proangiogenic/arteriogenic changes did not occur in sham-
operated AM-overexpressing mice where the expression of
AM receptor component RAMP2 is signiﬁcantly suppressed,
possibly through feedback inhibition. Such tissue selectivity
could be an advantage for clinical application of AM in
patients with SIVD; AM-induced arteriogenesis and angio-
genesis could be induced only in hypoperfused tissue.
9.5. Bone Marrow Transplantation. Therapeutic use of bone-
marrow-derived cells has been shown to ameliorate func-
tional deﬁcits after stroke and is accompanied by augmenta-
tionofangiogenicandregenerativeresponses[76].Although
early functional improvement has been noted within days of
treatment, its precise mechanism remains to be elucidated. A
recent study has demonstrated that administration of bone
marrow mononuclear cells (BMMNCs) induces immediate
endothelial nitric oxide synthase-dependent vasodilation in
ischemic femoral arteries [77].
In BCAS mice, BMMNC treatment has been shown
to provide strong protection against WM damage, depen-
dent primarily on CBF recovery beginning from the early
phase, and the subsequent endogenous restorative response,
including angiogenesis, in a later phase [78]. Both of these
responses involve nitric oxide synthase activation. Despite
marked protection against WM damage, no direct structural
incorporationofdonorBMMNCstooligodendrogenesiswas
found, although a fraction of donor cells were found to
wrap around the microvessels with features suggestive of
pericytes [78, 79]. While a direct antiapoptotic eﬀect on
oligodendrocytes may be involved in the WM protection
[80], it is plausible that CBF recovery after BMMNC
treatment is suﬃcient to maintain WM integrity. Additional
investigation is therefore required to assess whether other
mechanisms such as direct structural incorporation or direct
antiapoptotic eﬀect of BMMNCs play a role in the WM
protection. The above ﬁndings suggest clinical applicability
of BMMNC treatment for SIVD management.
10. A New Concept of “Oligovascular Niche”
Recently, the concept of “oligovascular niche” has been
proposed, where crosstalk between the endothelial cells and
oligodendrocytes mediated by an exchange of soluble signals
(such as brain-derived neurotrophic factor and ﬁbroblast
growth factor) might play an important role in sustaining
oligodendrocyte homeostasis and WM integrity (Figure 4)
[81, 82]. In the oligovascular unit, endothelial cells release
trophic factors that promote oligodendrocyte precursorJournal of Aging Research 9
cell proliferation. Noncytotoxic levels of oxidative stress
or blockade of Src and Akt signaling prevents endothelial
trophic factors from supporting oligodendrocyte precursor
cells. Therefore, to treat or prevent WM damage in SIVD,
endothelial cells and oligodendrocytes should be protected
from being damaged due to hypoperfusion.
Since cerebral endothelial cells contribute to numer-
ous signaling cascades that help regulate brain homeosta-
sis and function [83], angio-/arteriogenesis and inhibi-
tion of oxidative damage in the cerebral endothelial cells
might lead to oligovascular protection—namely, successful
vascular growth and vasoprotection and preservation of
WM/oligodendrocyteintegrity—andpreventionofcognitive
decline after chronic cerebral hypoperfusion. Therefore,
the application of proangiogenic, antioxidative, and anti-
inﬂammatory factors, including the aforementioned drug-
and cell-based therapy, may oﬀer potential for the treatment
of WM changes and SIVD.
11. Summary and Conclusions
The BCAS model characterizing features of vascular cogni-
tive impairment with WM changes may serve as a powerful
tool for investigation of the molecular pathology of WM
lesions and in the design of therapeutic measures for
WM changes induced by chronic cerebral hypoperfusion.
Although these models do not (and no other current
models can) describe all features of SIVD [84], the BCAS
model may help further elucidate the mechanism by which
WM pathology and dementia progress in the elderly. Such
knowledge may signiﬁcantly enhance strategies to tackle
these disorders.
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